закрити [x]
приховати бюлетень | кошик

A biochimist works on a XAV-19 anti covid treatment (19)

190x60
New Rada

кошики

Ви повинні увійти в систему, щоб мати доступ до кошика

 

EN_01462003_1210
EN_01462003_1210

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1215
EN_01462003_1215

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1216
EN_01462003_1216

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1225
EN_01462003_1225

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1230
EN_01462003_1230

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1231
EN_01462003_1231

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1236
EN_01462003_1236

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1237
EN_01462003_1237

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1238
EN_01462003_1238

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1251
EN_01462003_1251

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1252
EN_01462003_1252

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1253
EN_01462003_1253

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, on January 25, 2021 in Nantes, western France. (Photo by LOIC VENANCE / AFP)

EN_01462003_1258
EN_01462003_1258

A biochimist carries samples as she works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)

EN_01462003_1259
EN_01462003_1259

A biochimist prepares samples as she works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)

EN_01462003_1260
EN_01462003_1260

A biochimist prepares samples as she works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)

EN_01462003_1261
EN_01462003_1261

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)

EN_01462003_1262
EN_01462003_1262

A biochimist prepares samples as she works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)

EN_01462003_1263
EN_01462003_1263

A biochimist prepares samples as she works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)

EN_01462003_1278
EN_01462003_1278

A biochimist works on a XAV-19 anti covid treatment as part of a clinical trial run at the Xenothera Biotech laboratory at Nantes University hospital, western France, on January 25, 2021. (Photo by LOIC VENANCE / AFP)